Shares of global pharmaceutical company Merck (NYSE:MRK) jumped 4.1% in the afternoon session after Wells Fargo upgraded the stock to "Overweight" from "Equal-Weight," citing confidence in the company ...

Wellington College International Pune is hosting its second annual Welly Colour Fest on November 29, 2025. This inter-school drawing competition invites children aged two to sixteen to showcase their ...

Thinking about whether Merck is a bargain or not? You’re not alone, plenty of investors are eager to know if now is the time to buy, hold, or stay away. Over the last month, Merck’s share price has ...

Merck's acquisition of Cidara Therapeutics for $9.2 billion focuses on CD388, a promising antiviral for influenza prevention. CD388, in Phase 3 trials, has FDA breakthrough therapy designation, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The plant will bring ...

A billion-dollar tsunami of life sciences development is hitting Virginia, with multinational pharmaceutical firm Merck as the latest to join the wave. The New Jersey-based pharma giant has begun ...

Merck on Monday announced the groundbreaking of its new Virginia pharmaceutical manufacturing facility, a cornerstone of the company’s $70 billion U.S. investment strategy. The 400,000-square-foot ...

Merck & Co. will build a $3 billion pharmaceutical manufacturing facility in Elkton that is expected to create 500 jobs, Gov. Glenn Youngkin and the company announced at a ceremonial groundbreaking ...

Merck's $70 billion US investment plan includes a $3 billion facility in Virginia, creating 500 jobs and enhancing pharmaceutical manufacturing capabilities. Additional investments include a $1 ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. BERLIN — At a prime-time session on Saturday at a major cancer conference ...

Merck has increased its dividend for 14 consecutive years. Its 10-year dividend growth rate of 5.4% is only decent. Merck increased its revenue from $39.5 billion in FY 2015 to $64.2 billion in FY ...

Merck is attractively valued, boasting strong free cash flow, robust margins, and a leading position in oncology with Keytruda. MRK faces a looming patent cliff for Keytruda in 2028, but a strong late ...